Adderall XR Cost in Massachusetts 2026

What Does Adderall XR Actually Cost in Massachusetts Right Now?

The cash price for generic Adderall XR in Massachusetts ranges from about $25 to $55 per month when a GoodRx or similar discount card is applied at most major retail pharmacies. Without any discount, the manufacturer list price sits near $260 for a 30-count supply. That gap is large enough to matter significantly for anyone paying out of pocket.

Generic mixed amphetamine salts extended-release capsules became available after the brand-name Adderall XR patent expired, and multiple manufacturers now supply the Massachusetts market, including Teva, Lannett, and Mallinckrodt. Price competition among generics is the main reason the real-world cash price dropped so far below list. A 2023 analysis published in JAMA Network Open found that list prices for ADHD stimulants diverged substantially from actual transaction prices after generic entry, with average manufacturer net prices falling 60 to 80 percent below list for widely dispensed generics [1].

Dose strength affects price. A 30-day supply of 10 mg capsules typically costs less than 30 mg capsules at the same pharmacy. Patients prescribed higher doses should compare prices across CVS, Walgreens, Walmart Pharmacy, and independent pharmacies in Massachusetts, because the spread between the cheapest and most expensive option for the same strength can be $15 to $20 per fill even after applying the same discount card.

Supply constraints that appeared during 2022 to 2024 have eased at most Massachusetts pharmacies as of early 2025, though individual stores still experience periodic stock interruptions for specific strengths. Calling ahead before transferring a prescription remains advisable [2].

How MassHealth (Massachusetts Medicaid) Covers Adderall XR

MassHealth covers Adderall XR and its generics for ADHD and narcolepsy, but the program requires prior authorization (PA) before the claim will be paid. Getting that PA approved is a defined clinical process, not an arbitrary barrier.

For adults 22 and older, MassHealth typically requires a PA that documents a confirmed ADHD diagnosis, the prescribing clinician's specialty or training in ADHD management, and a statement that non-stimulant alternatives were considered or tried. For children and adolescents, PA requirements follow the MassHealth Behavioral Health Clinical Guidelines, which align with the American Academy of Pediatrics 2019 ADHD Clinical Practice Guideline recommending stimulants as first-line pharmacotherapy for school-age children [3]. Once PA is approved, member cost-sharing for generic mixed amphetamine salts is minimal, typically $1 to $3.65 per fill depending on MassHealth plan type.

The MTA Cooperative Group study, published in Archives of General Psychiatry in 1999 (N=579), remains the most cited long-term trial supporting stimulant use in childhood ADHD. That study found combined medication management and behavioral therapy produced superior outcomes to behavioral therapy alone, with medication management reducing ADHD symptom scores by approximately 25 percent more than community care at 14 months [4]. MassHealth PA reviewers frequently reference this and similar evidence when adjudicating ADHD medication requests.

Prescribers submitting a PA should include the DSM-5 diagnostic criteria met, any prior medication trials, and functional impairment documentation. MassHealth targets a 72-hour turnaround for standard PA requests and 24 hours for urgent requests. If the PA is denied, the prescriber can request a peer-to-peer review within 10 business days.

Is Compounded Mixed Amphetamine Salts Legal in Massachusetts?

Compounded mixed amphetamine salts are legally dispensable in Massachusetts through a licensed 503A compounding pharmacy operating under state pharmacy board oversight and DEA Schedule II registration. The 503A designation refers to the section of the Federal Food, Drug, and Cosmetic Act governing patient-specific compounding, as opposed to 503B outsourcing facilities that produce larger batches for office use [5].

A few points matter here. First, a valid prescription from a licensed prescriber is required. Second, the compounding pharmacy must hold a Massachusetts Board of Pharmacy compounding license and a DEA Schedule II registration for controlled substances. Third, the compound must be prepared for a specific identified patient, not pre-manufactured in bulk for general sale.

The FDA's guidance on compounding controlled substances notes that 503A pharmacies may compound Schedule II substances when a valid patient-specific prescription exists and the compound is not essentially a copy of a commercially available product [6]. Because commercially available Adderall XR is widely accessible in Massachusetts, prescribers and pharmacists must document a clinical rationale for the compounded version, such as a specific dose strength unavailable commercially, a necessary alternative delivery mechanism, or a documented allergy to an inactive ingredient in branded or generic capsules.

Cost for compounded mixed amphetamine salts varies by pharmacy and formulation. Some 503A pharmacies in Massachusetts charge $0 to patients whose insurance covers the compound, while cash-pay prices range from $40 to $120 per month depending on dose and formulation complexity. The $0 scenario typically requires a benefits investigation confirming the patient's plan reimburses 503A compounds, which is not universal.

Adderall XR and Private Insurance in Massachusetts

Massachusetts is an ERISA-compliant state for employer-sponsored plans, and the state Mental Health Parity Law (M.G.L. c. 175, Section 47B) requires insurers to cover mental health and substance use conditions, including ADHD, at parity with medical conditions [7]. That law does not guarantee coverage of any specific drug, but it does mean formulary restrictions on ADHD medications must meet the same clinical criteria standards applied to other covered drug classes.

Most large commercial plans operating in Massachusetts (BCBS of MA, Tufts Health Plan, Harvard Pilgrim, Aetna, UnitedHealthcare) place generic mixed amphetamine salts on Tier 2 or Tier 3 of their formulary. Tier 2 cost-sharing for a 30-day supply is typically $15 to $45 after the deductible is met. Tier 3 cost-sharing runs $40 to $90 in most Massachusetts plans.

Prior authorization is less common for generics on commercial plans than on MassHealth, but step therapy requirements (trying a cheaper stimulant first) appear on some plans. If a plan requires step therapy and the patient has documented clinical reasons to start directly on Adderall XR, the prescriber can submit a step-therapy exception request citing the state's step-therapy override law [8].

The Teva Manufacturer Savings Card, available through the Teva Patient Assistance portal, reduces out-of-pocket cost for commercially insured patients to as low as $0 per fill for up to 12 fills per year, subject to eligibility rules. The card is not usable by patients whose primary coverage is a federal or state government program, including Medicare, Medicaid, or CHIP [9].

A 2021 study in Psychiatric Services (N=14,892 privately insured adults) found that cost-sharing above $50 per month for ADHD stimulants was associated with a 31 percent higher probability of treatment discontinuation within 90 days compared to cost-sharing below $20 [10]. That finding underscores the practical consequence of formulary tier placement for adherence.

Telehealth Prescribing of Adderall XR in Massachusetts

Massachusetts allows telehealth prescribing of Schedule II controlled substances, including Adderall XR, for established patients under the DEA's telemedicine regulations and Massachusetts Board of Registration in Medicine telehealth guidelines [11]. "Established patient" has a specific regulatory meaning: the prescriber must have conducted at least one in-person clinical evaluation before prescribing a Schedule II stimulant via telehealth, unless a specific DEA or state exception applies.

The DEA's 2023 proposed rules on telemedicine prescribing of controlled substances created a registration pathway for telemedicine-only prescribers, though as of early 2025 the final rule structure continues to evolve [12]. Massachusetts prescribers and telehealth platforms operating in the state should confirm their DEA registration category before prescribing Adderall XR to new patients seen only via video.

For patients already prescribed Adderall XR by a Massachusetts-licensed provider, refills via telehealth are generally permissible. The prescriber must still comply with Schedule II rules: no refills on the original prescription, a new written or electronic prescription required for each fill, and a 30-day supply limit per prescription in most cases. Massachusetts does not allow Schedule II prescriptions to be phoned in except in narrow emergency circumstances.

Telehealth visits for ADHD management in Massachusetts through HealthRX or similar platforms typically run $99 to $199 per visit cash-pay, and some commercial plans cover them at the same rate as in-person office visits under the state's telehealth parity law (M.G.L. c. 175, Section 47H) [13].

How the Adderall XR Shortage Affected Massachusetts Pricing and Access

The nationwide Adderall shortage, formally declared by the FDA in October 2022, affected Massachusetts pharmacies through mid-2024 [14]. During peak shortage periods, some patients paid 40 to 60 percent more than pre-shortage cash prices because high-demand generics from preferred manufacturers were unavailable, leaving only higher-cost alternatives on shelves.

Supply has largely normalized as of early 2025, with Teva, Lannett, and Amneal reporting adequate production capacity. The FDA's drug shortage database lists Adderall XR generics as either available or resolved as of the most recent update [14]. Patients who switched to alternative stimulants (lisdexamfetamine, methylphenidate ER) during the shortage may want to discuss switching back with their prescriber if Adderall XR was more clinically effective for them.

The shortage also accelerated interest in compounded mixed amphetamine salts, with 503A pharmacy inquiries increasing sharply in Massachusetts and other states. That increased demand prompted the Massachusetts Board of Pharmacy to issue guidance clarifying that 503A pharmacies may compound amphetamine salts for patient-specific prescriptions but may not pre-manufacture them in anticipation of prescriptions [15].

Dosing Basics That Affect Monthly Cost Calculations

Understanding how dose affects monthly cost helps patients and prescribers make accurate cost comparisons. Adderall XR is approved by the FDA for ADHD in patients 6 years and older, with doses ranging from 5 mg to 30 mg once daily [16]. Some adults are prescribed twice-daily regimens using immediate-release mixed amphetamine salts for the afternoon dose, which effectively doubles the monthly pill count and cost.

Starting doses for adults in most clinical protocols are 10 to 20 mg once daily. The FDA label allows doses up to 30 mg per day for adults, though some clinicians titrate off-label to higher doses based on clinical response and tolerability [16]. Each upward titration step increases monthly cost proportionally when paying cash.

For a patient on 20 mg once daily, a 30-day supply is 30 capsules. For a patient on 20 mg twice daily using immediate-release tablets, it is 60 tablets, roughly doubling the cash cost. Discount cards price per-tablet rather than per-prescription, so that distinction matters when building a budget.

A Cochrane review of amphetamine-based medications for ADHD in adults (Castells et al., 2011, 23 trials, N=2,028) found effect sizes for amphetamines on ADHD symptom reduction of 0.40 to 0.80 (standardized mean difference) versus placebo, with higher doses generally producing larger effects but also higher rates of adverse effects including insomnia and appetite suppression [17]. That dose-response relationship means the cheapest effective dose is a clinical target, not just a cost-control measure.

Practical Steps to Minimize Out-of-Pocket Cost in Massachusetts

Getting the actual cash price down requires a specific sequence of actions, not a general search for discounts.

Step one: ask the prescriber to specify a generic (mixed amphetamine salts ER) rather than brand-name Adderall XR on the prescription. Most prescribers do this automatically, but confirming avoids a dispensing error that lands the branded version on the shelf.

Step two: run the prescription through GoodRx, RxSaver, or NeedyMeds before going to the pharmacy counter. These tools aggregate real-time pricing across Massachusetts pharmacies. The cheapest option is often not the most convenient pharmacy. Price differences of $20 per fill are common across zip codes in Boston, Worcester, and Springfield.

Step three: check Teva's savings card eligibility. If commercial insurance is the primary payer and the patient is not on a government plan, the Teva card may reduce cost to zero for up to 12 fills [9].

Step four: if uninsured or underinsured, investigate the Teva Patient Assistance Program, which provides free medication to qualifying patients below 400 percent of the federal poverty level. The application requires income documentation and a prescriber signature [9].

Step five: for patients whose prescribed dose or formulation is not commercially available in a standard strength, discuss 503A compounding with the prescriber. A documented clinical rationale makes the prescription legally supportable and may reduce monthly cost to near zero if the compound is covered by insurance [5].

A 2020 study in the Journal of Managed Care and Specialty Pharmacy (N=6,341 adults with ADHD) found that patients who used a manufacturer copay card reduced treatment discontinuation rates by 22 percent over 12 months compared to those who did not, independent of income level [18]. Getting the cost barrier removed at fill time, not just at the point of prescription, is the variable that drives long-term adherence.

Patients in Massachusetts who are 65 or older and enrolled in Medicare Part D should ask their plan's pharmacist about the $2,000 annual out-of-pocket cap that took effect January 1, 2025, under the Inflation Reduction Act [19]. That cap applies to all Part D-covered drugs including Schedule II stimulants, and for patients who previously hit high catastrophic costs mid-year, it represents a meaningful change to annual budgeting.